[ad_1]
A study by CIBERDEM and CIBERCV teams at the Bellvitge Biomedical Research Institute (IDIBELL) and the Universitat Rovira I Virgili (URV) of Tarragona has identified a biomarker that allows to evaluate heart failure (IC) In patients with iron deficit (DH).
The work, published in the magazine Biomoleculesprovides evidence between levels of Growth differentiation factor 15 (GDF15) and the Right ventricle dysfunction, deteriorated functional capacity and heart failurespecifically in a group of patients with IC and DH, CIBER reports in a statement.
He GDF15 is a very relevant group of protein “ for intercellular communication and acts as a biomarker in cardiovascular diseases and cancer.
According to the researcher in the area of diabetes and associated metabolic diseases of CIBER in the URV and one of the study coordinators, Ricardo Rodríguez-Calvothe study shows that serum levels of GDF15 provide a “solid discriminatory capacity” and improve the performance of a model of Logistics regression for ischemic IC.
That supports its potential as a “valuable tool” for classify ischemic causes in patients with heart failure and iron deficit.
“High prevalence”
The researcher of the Cardiovascular Area of the CIBER and director of the Heart Diseases Area of the Bellvitge Hospital, Josep Comín-Colletpoints out that Non -anemic iron deficiency has a “high prevalence” among patients with heart failure and has been related to a worse prognosis.
“GDF15 has been related to Atherosclerotic cardiovascular disease, IC and iron metabolismbut its role of GDF15 as a biomarker potential for IC in patients with DH has not been completely explored, “says Comín-Collet.
[ad_2]
Source link
